All Articles

Binah Capital Group swings from a loss to a profit in Q2, crediting its unique model for empowering independent advisors. Is this a fluke or a new industry benchmark?

New data reveals a major shift in Malaysian travel: short, two-day domestic trips are in. We explore the economic and tech forces driving this trend.

Firm Capital reports falling profits but holds its dividend steady. With a high payout ratio and a surge in new lending, is this a sign of resilience or risk?

Stardust Power is breaking ground on a key US lithium refinery, but thin cash reserves and a reliance on future funding raise critical questions.

Agoda and Singapore's Tourism Board are ditching old marketing playbooks for a new AI-powered strategy to create hyper-personalized travel and a smarter economy.

Greenlane Renewables posts a profit while doubling R&D and forging a key partnership with Panasonic. Is this the model for sustainable innovation?

TWFG just secured a $125M credit facility. It's not just about money; it's a strategic move to accelerate acquisitions and pioneer an AI-driven future for insurance.

Grandstand's new Rollcard aims to be the go-to debit card for high rollers, but this fintech pivot is a high-stakes bet on navigating a minefield of regulatory risks.

With a novel drug platform and new funding, Akari Therapeutics aims to redefine cancer therapy. But can its groundbreaking science outpace a ticking financial clock?

The Chinese robotics firm posted record revenue but a staggering $5.6M loss. Is this a strategic masterstroke or a reckless bet on a future that may never pay off?

Fortress Biotech's Q2 net loss masks a cash-rich strategy. A $117M cash surge and major pipeline wins reveal a model built for the long haul.

With $4.4M in new funding, Clarity Systems is deploying AI scanners to see inside returns, fighting fraud without penalizing honest shoppers.

Caribou Biosciences reports impressive clinical data for its allogeneic CAR-T therapies, but the path to broader patient access hinges on a critical hurdle: funding.

MDB Capital celebrates a string of successful IPOs but reports a staggering $16.1M loss, putting its unique 'public venture' model under intense scrutiny.

Intellicheck posts record Q2 revenue and a fifth straight profitable quarter, but a key client's pivot to a multi-vendor model tests its diversification strategy.

With regulatory winds at its back in the US and EU, Cibus is pushing to commercialize its non-GMO tech. Can new leadership turn R&D into revenue before cash runs out?

dLocal posts a stunning 92% surge in payment volume, cementing its emerging market dominance. Yet, a closer look at profitability reveals a complex balancing act.

Don't let headline numbers fool you. True North's Q2 reveals a 7.1% NOI surge and 96% occupancy, a testament to its sharp portfolio management.

Kyntra Bio's Q2 profit was driven by a one-time accounting gain, masking operating losses. Now, the firm bets its future on two critical Q4 data readouts.

Plunging revenues and a staggering net loss push IM Cannabis to the edge, forcing a desperate and bizarre strategic pivot from medical marijuana to military drones.